Background {#Sec1}
==========

The platelet proteome is an untapped resource for identifying proteins that may reflect a disease process. Platelets are easily accessible and free from major highly abundant proteins making them an attractive model for proteomic studies. Platelets change the composition of their proteins in diseases such as Alzheimer's, cancer, diabetes, coronary artery disease and acute coronary syndrome \[[@CR1]--[@CR4]\]. Platelets are largely under-studied in heart failure, yet evidence indicates that both platelet function \[[@CR5], [@CR6]\] and platelet-derived proteins such as adhesion molecules and the natriuretic peptide receptor-C \[[@CR7]--[@CR10]\] are altered in heart failure. Therefore, changes in the platelet proteome may allow for the identification of proteins that influence the disease process in heart failure.

Heart failure with preserved ejection fraction (HFpEF) affects almost 50 % of patients with heart failure and is increasing in prevalence \[[@CR11]\], yet the pathophysiological mechanisms are poorly understood. HFpEF is associated with diabetes, hypertension, renal dysfunction, atrial fibrillation and obesity. The systemic inflammatory state induced by these co-morbidities is predictive of HFpEF \[[@CR12], [@CR13]\]. Platelets are both contributors and responders of inflammatory processes \[[@CR14]\]. Considering there are no targeted therapies for HFpEF and morbidity and mortality are high, it is paramount to identify biomarkers associated with HFpEF and clarify their mechanistic role in clinical heart failure in order to develop targeted treatments. Consequently, by examining the platelet proteome of subjects with HFpEF, there is the potential to identify proteins that may provide insight into the disease mechanisms.

We established a novel bed-to-bench translational system to identify potential mediators of HFpEF using both platelet proteome analysis and mechanistic studies in induced pluripotent stem cell-derived cardiomyocytes. The broad utility of this strategy is to incorporate bioactivity studies into guiding the selection of proteins from proteomic studies for further investigation. We sought to compare the platelet proteome among subjects with HFpEF in the uncompensated (hospitalized) state, compensated (outpatient) state, and controls combined with validation in plasma samples from an external cohort and bioactivity studies using human induced pluripotent stem cell (iPSC)-derived cardiomyocytes. We hypothesized that \[[@CR1]\] platelet proteomic analysis would successfully identify a protein associated with HFpEF, and \[[@CR2]\] human iPSC-derived cardiomyocytes treated with recombinant proteins could serve as further validation by demonstrating phenotypic changes in cardiomyocyte calcium handling, which is altered in HFpEF.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

For the discovery phase, subjects ≥50 years old presenting with New York Heart Association class II--III heart failure symptoms, a left ventricular ejection fraction (LVEF) \>50 %, echocardiographic evidence of diastolic dysfunction and increased LV filling pressure were evaluated at the Medical College of Wisconsin between June 2012 to December 2013 for participation in this study. Increased LV filling pressures were defined as E/e′ ≥ 15, or E/e′ ≥ 8 and ≤ 15 with either a BNP ≥ 200 pg/ml or a left atrial (LA) volume index \> 40 ml/m^2^. Subjects were excluded if they had a clinical condition that potentially changed the platelet or plasma proteomic profile independent of HFpEF such as uncontrolled diabetes, an active infection or inflammatory disorder, chronic renal failure requiring dialysis, severe liver disease, malignancy, acute myocardial infarction, chronic obstructive pulmonary disease requiring steroids, or recent surgical or invasive cardiac procedures. Subjects were excluded if they had other cardiac causes for their symptoms such as severe valvular disease, amyloidosis, or hypertrophic cardiomyopathy. Blood was drawn from the nine subjects enrolled in the study (HFpEF hospitalized group). Five of these subjects (HFpEF outpatient group) returned ≥2 weeks after discharge for second blood draw. Subjects with an LVEF ≥50 % and without evidence of increased LV filling pressures served as the control group.

For further biomarker validation, an additional set of 25 HFpEF subjects and 18 age and co-morbidity matched control subjects were recruited from Northwestern University. All subjects gave written informed consent to participate in the study. The Institutional Review Board at the Medical College of Wisconsin and Northwestern University approved the respective study protocols, which conformed to the principles of the Declaration of Helsinki.

Reagents {#Sec4}
--------

Supplies and other reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless specified. Recombinant S100A8 was purchased from Creative BioMart (Shirley, NY).

Platelet preparation {#Sec5}
--------------------

Blood was separated into serum and platelet fractions. Platelets were extensively washed in buffer (45 mM sodium citrate, 25 mM citric acid, 80 mM [d]{.smallcaps}-glucose). During all steps, care was taken to avoid activation of platelets. Flow cytometry with anti-CD41 (Life Technologies, Grand Island, NY) and anti-P-selectin (BioLegend, San Diego, CA) was performed to assess for platelet activation (Additional file: [1](#MOESM1){ref-type="media"}. Figure S1). Microscopy confirmation verified that the purified platelets had leukocyte and red blood cell contamination that was less than 0.02 and 1 %, respectively (Additional file: [2](#MOESM2){ref-type="media"}. Figure S2).

Global proteomic studies {#Sec6}
------------------------

Platelets from individual samples were resuspended in lysis buffer (125 mM Tris pH 6.8, 4 % SDS, 10 % glycerol, 5 % β-mercaptoethanol, Roche Complete Protease Inhibitor, Thermo HALT Phosphatase Inhibitor Cocktail). After determining protein concentration, the protein sample was separated by 1-dimensional SDS-PAGE gel (Bis-Tris 4--12 %) with internal DNA markers as described in our earlier publication \[[@CR15]\]. The gel was stained with indoine blue and divided into three pieces. The proteins were reduced with 100 mM dithiotreitol (DTT) in 25 mM NH~4~HCO~3~ for 30 min at 56 °C and alkylated with 55 mM iodoacetamide (IAA) in 25 mM NH~4~HCO~3~ for 30 min at room temperature followed by trypsin digestion overnight. Peptides were extracted with 0.1 % trifluoroacetic acid (TFA) and 70 % acetonitrile/5 % TFA in water, respectively. Extracts were dried in a Speedvac and subsequently acidified to 0.1 % TFA. The samples were desalted using a ZipTip (C18).

For biomarker discovery, all samples were subject to tandem mass spectrometry. Three injection replicates of each fraction (three fractions per sample) were run on an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific). For each injection replicate, 1.5 µl sample was separated via C18 column over the course of a 150 min gradient from buffer A (2 % acetonitrile, 98 % H~2~O, 0.1 % formic acid) to buffer B (98 % acetonitrile, 2 % H~2~O, 0.1 % formic acid). The gradient program began with 2 min at 98 % A, followed by a 3 min ramp to 95 % A, a 115 min ramp to 60 % A, a 15 min ramp to 2 % A, 3 min at 2 % A, 2 min ramp to 98 % A, then a 10 min equilibration in 98 % A. MS1 scans were detected in the FTMS section of the Orbitrap Velos in profile mode at a resolution of 30,000 (full width of peak at half-maximum at 400 m/z). The ten most abundant parent ions from each MS1 scan were selected for fragmentation via collision induced dissociation. Results of SEQUEST searches against UniProt human database (version April 2013) and all nine runs of each sample were combined using Visualize software. Visualize software was also used to generate comparison data \[[@CR16]\]. The protein lists include proteins identified with at least five scans that were observed with peptide probability \>0.85.

S100A8 expression {#Sec7}
-----------------

S100A8 levels were determined using a S100A8 enzyme-linked immunoassay kit from MBL International (Des Plaines, IL).

Induced pluripotent stem cell induced-cardiomyocyte differentiation {#Sec8}
-------------------------------------------------------------------

The induced pluripotent stem cell (iPSC) line used in this study was a generous gift from Dr. Stephan Duncan. This iPSC line was generated from human foreskin fibroblasts and previously characterized \[[@CR17]\]. The iPSC line was maintained on Matrigel (BD Biosciences, San Jose, CA) in mTeSR-1 media (Stem Cell Technologies, BC, Canada) and differentiated into cardiomyocytes according to published protocols \[[@CR18], [@CR19]\]. Differentiated cells were maintained in cardiomyocyte maintenance media (RPMI/B27; Life Technologies, Grand Island, NY). For all experiments, 35 ± 5 day old contracting cardiomyocytes were used.

Electrophysiology {#Sec9}
-----------------

Action potentials were recorded from the human iPSC-derived cardiomyocytes using the current clamp configuration of the patch clamp technique, as previously described \[[@CR20], [@CR21]\]. Briefly, patch pipettes were pulled from borosilicate glass capillaries (King Precision Glass, Claremont, CA) with a micropipette puller (PC-10; Harishige, Tokyo, Japan) and heat polished using a microforge (MF-830; Narishige). The pipette resistances ranged from 3--5 MΩ when filled with the intracellular recording solution. This pipette solution contained 60 mM K-glutamate, 50 mM KCL, 10 mM HEPES, 1 mM MgCl~2~, 11 mM EGTA, 1 mM CaCl~2~, and 5 mM K~2~-ATP (pH adjusted to 7.4 with KOH). The extracellular bath solution contained 132 mM NaCl, 4.8 mM KCl, 1.2 mM MgCl~2~, 1.0 mM CaCl~2~, 5 mM dextrose, and 10 mM HEPES (pH adjusted 7.4 with NaOH). Action potentials were recorded using a Multiclamp 700B amplifier and Digidata 1440A interface (Molecular Devices, Sunnyvale, CA). pClamp 10 software (Molecular Devices) was used for data acquisition and analysis. Spontaneously beating nodal-, atrial-, and ventricular-like cells were characterized based on the maximum rate of depolarization (dV/dt), action potential duration (APD) at 50 and 90 % repolarization, and maximum diastolic potential. Recordings were conducted at physiological temperature (37 °C). The temperature of the recording chamber was controlled via a temperature control unit (TC 344B; Warner Instruments, Hamden, CT).

Ratiometric Ca^2+^ microfluorometry {#Sec10}
-----------------------------------

Briefly, human iPSC-derived cardiomyocytes plated on coverslips were exposed to Fura-2-AM (5 µM) for 30 min at room temperature, washed three times with extracellular bath solution, and given 30 min for de-esterification. For Ca^2+^ microfluorometry, the fluorophore was excited alternately with 340 and 380 nm wavelength illumination and images were acquired at 510 nm through a 20× objective. Recordings from each cell were obtained at a rate of 3 Hz. After background subtraction, the fluorescence ratio R for individual cell was determined as the intensity of emission during 340 nm excitation (I~340~) divided by I~380~, on a pixel-by-pixel basis. Activation-induced transients were generated by depolarization produced by microperfusion application of 50 mM KCl \[[@CR22]\].

Statistical analysis {#Sec11}
--------------------

Data is presented as either mean ± SD or as total percentage. Continuous variables were compared using the Student t test, assuming equal variance and dichotomous variables were compared using the Fisher exact test. Mass spectrometry measurements between groups were compared for either the presence (assigned a number value of 1) or absence (assigned a number of value of 0) of the protein identified in the sample using non-parametric Wilcoxon rank-sum tests without adjusting for multiple testing. Mass spectrometry data analysis was performed by the biostatical consulting service at the Medical College of Wisconsin.

Results {#Sec12}
=======

Clinical and echocardiographic characteristics of the discovery cohort {#Sec13}
----------------------------------------------------------------------

As described in Table [1](#Tab1){ref-type="table"} the median age of the HFpEF subjects is slightly greater than the control subjects (p = 0.04). The HFpEF group had a higher incidence of atrial fibrillation and cerebral vascular accident/transient ischemia in comparison to control subjects. Although not statistically significant, HFpEF subjects were more likely to have diabetes, coronary heart disease, hyperlipidemia and a distant smoking history. A significant number of HFpEF subjects were taking beta blockers compared to the control group. Echocardiogram studies confirmed the presence of diastolic dysfunction and increased LV pressure in the HFpEF group (Table [2](#Tab2){ref-type="table"}). Left atrial volume indices were significantly elevated along with an increase in LV wall thickness in the HFpEF group compared to control.Table 1Clinical characteristics of subjectsCharacteristicHFpEF (n = 9)Control (n = 7)p value \<0.05Age, years75 ± 1062 ± 130.03Women (%)7571n.s.Body mass index33 ± 933 ± 10n.s.Hypertensive (%)6775n.s.Hyperlipidemia (%)6763n.s.Diabetes (%)5625n.s.Coronary artery disease (%)5629n.s.h/o CVA/TIA (%)5000.02h/o Afib (%)780\<0.001Smoking history (%)10029\<0.001Current smoker (%)1114n.s.Former smoker (%)8914n.s.MedicationsACEI/ARB (%)5057n.sBeta-blocker (%)100500.009Aldosterone antagonist (%)00n.s.Statin (%)7557n.s.Diuretic (%)4443n.s.*h/o* history of; *CVA/TIA* cerebral vascular accident/transient ischemic attack, *Afib* atrial fibrillation, *ACEI/ARB* angiotensin converting enzyme inhibitor/angiotensin receptor blockerThe p value was calculated using two tailed student t-tests for numerical variables and using Chi squared and Fisher's exact tests for categorical valuesTable 2Echocardiographic characteristics of subjectsCharacteristicHFpEF (n = 9)Control (n = 7)p value \<0.052D EchocardiographyLA volume index, ml/m^2^49 ± 1532 ± 7.70.018LV internal diameter, cm4.64 ± 0.374.73 ± 0.08NSInterventricular septum, cm1.25 ± 0.120.92 ± 0.010.001Posterior wall, cm1.20 ± 0.180.88 ± 0.090.004LV mass index, g/m^2^112 ± 2090 ± 45NSEjection fraction,  %55 ± 660 ± 3NSDoppler dataE peak, cm/s86.6 ± 2668.0 ± 5.8NSe′ peak6.9 ± 1.667.7 ± 1.03NSE/e′ ratio14.4 ± 5.139.28 ± 0.37NSDiastolic dysfunction, %10014\<0.001*LA* left atrium, *LV* left ventricleThe p value was calculated using two-tailed student t-tests

Overall description of proteomic findings {#Sec14}
-----------------------------------------

Global proteomic experiments were performed using 21 separate platelet preparations. Combining these experiments, a total of 6102 proteins were identified with at least five scans with a protein probability of \>0.85. The HFpEF hospitalized group had a total of 5546 proteins, the HFpEF outpatient group had a total of 4854 proteins and the control group had a total of 5498 proteins identified. A total of 4172 proteins were found to be shared among all three groups. When comparing two groups, 321 proteins were identified as being shared amongst the outpatient and control group. A total of 361 proteins were found in both the hospitalized and outpatient groups and a total of 848 proteins were found in both the control and hospitalized groups. The number of unique proteins in each group consisted of 165 proteins in the HFpEF hospitalized group, 78 proteins in the HFpEF outpatient group, and 157 unique proteins in the control group (Fig. [1](#Fig1){ref-type="fig"}). To assess for possible contamination from other blood cells, the data set was scanned for the presence of CD45 and MHC II chains; proteins that are expressed in leukocytes. These proteins were not found in the data set; therefore, the contamination from leukocytes was likely to be minimal. However, complement C5 and β-2-glycoprotein were identified in the data sets denoting some serum contamination was present.Fig. 1Global proteomic analysis of platelets identifies 6102 proteins. The Venn diagram displays he results of the analysis of platelet proteins from the individual subjects by in-depth LC--MS/MS. In total, 6102 proteins were identified with 4172 common among all data sets. There were 165, 78, and 157 proteins identified that were unique to the HFpEF Symptomatic, HFpEF outpatient and Control groups

Unique proteins in each study group {#Sec15}
-----------------------------------

The platelet proteome from nine subjects were analyzed in the HFpEF hospitalized group, five subjects in the HFpEF outpatient and seven subjects in the control group. The unique proteins identified with a scan count of \>9 are listed in Table [3](#Tab3){ref-type="table"}. In addition after applying the non-parametric Wilcoxon rank-sum test, 37 proteins were found to be more prevalent amongst the combined HFpEF groups than with the control and 77 proteins were identified that were found to be more prevalent amongst the control with a p value \<0.05. These proteins are listed Table [4](#Tab4){ref-type="table"}.Table 3List of unique proteins identified in each group with \>9 scans totalProteinAccessionDescriptionPresent only in HFpEF symptomatic group NALP2Q9NX02NACHT, LRR and PYD domains-containing protein ZEP3Q5T1R4Transcription factor HIVEP3 MET25Q8N6Q8Methyltransferase-like protein 25 SCAF8Q9UPN6Protein SCAF8 CC105Q8IYK2Coiled-coil domain-containing protein 105 FILAP20930Filaggrin MEG11A6BM72Multiple epidermal growth factor-like domains protein 11 F19A2Q8N3H0Protein FAM19A2 GRM1Q13255Metabotropic glutamate receptor YP010Q96M66Putative uncharacterized protein FLJ32790 PSMD4P5503626S proteasome non-ATPase regulatory subunit 4 PCCAP05165Propionyl-CoA carboxylase alpha chain, mitochondrial TCPR2O15040Tectonin beta-propeller repeat-containing protein KPRPQ5T749Keratinocyte proline-rich protein GTPB5Q9H4K7GTP-binding protein 5 CV031O95567Uncharacterized protein C22orf31 TFB2 MQ9H5Q4Dimethyladenosine transferase 2, mitochondrial SPXN4Q5MJ08Sperm protein associated with the nucleus on the X chromosome N4 PF21AQ96BD5PHD finger protein 21APresent only in HFpEF asymptomatic group H2A1HQ96KK5Histone H2A type H2A3Q7L7L0Histone H2A type 3 POK7Q9QC07HERV-K_1q23.3 provirus ancestral Pol protein CC127Q96BQ5Coiled-coil domain-containing protein 127 CC85CA6NKD9Coiled-coil domain-containing protein 85C WDR75Q8IWA0WD repeat-containing protein 75 CXCL3P19876C-X-C motif chemokine 3 RGPS1Q5JS13Ras-specific guanine nucleotide-releasing factor RalGPS1 CXCL2P19875C-X-C motif chemokine 2 CHMP7Q8WUX9Charged multivesicular body protein 7 CK2N2Q96S95Calcium/calmodulin-dependent protein kinase II inhibitor 2 CHIT1Q13231Chitotriosidase-1 NOX1Q9Y5S8NADPH oxidase 1 RBY1CP0DJD4RNA-binding motif protein, Y chromosome, family 1 member C WFDC3Q8IUB2WAP four-disulfide core domain protein 3 ABCBBO95342Bile salt export pump HHATQ5VTY9Protein-cysteine N-palmitoyltransferase HHAT MID51Q9NQG6Mitochondrial dynamic protein MID51 LMNB1P20700Lamin-B1Present only in control group MY15BQ96JP2Putative unconventional myosin-XVB CC020Q8ND61Uncharacterized protein C3orf20 MCTS1Q9ULC4Malignant T cell-amplified sequence 1 KSR1Q8IVT5Kinase suppressor of Ras 1 PRP6O94906Pre-mRNA-processing factor 6 DDX59Q5T1V6Probable ATP-dependent RNA helicase DDX59 AL1A3P47895Aldehyde dehydrogenase family 1 member A3 PCCBP05166Propionyl-CoA carboxylase beta chain, mitochondrial HNRCLO60812Heterogeneous nuclear ribonucleoprotein C-like 1 BIRC3Q13489Baculoviral IAP repeat-containing protein 3 NDUF4Q9P032NADH dehydrogenase 1 alpha subcomplex assembly factor 4 MIRO2Q8IXI1Mitochondrial Rho GTPase 2Present in HFpEF symptomatic and HFpEF asymptomatic groups but not control group MBD5Q9P267Methyl-CpG-binding domain protein 5 RRBP1Q9P2E9Ribosome-binding protein 1 ZNF79Q15937Zinc finger protein 79 DCNL5Q9BTE7DCN1-like protein 5 RGS3P49796Regulator of G-protein signaling 3 TMOD2Q9NZR1Tropomodulin-2 MYO5BQ9ULV0Unconventional myosin-Vb SC24DO94855Protein transport protein Sec24D SHIP1Q92835Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 ASIC1P78348Acid-sensing ion channel 1 DMXL1Q9Y485DmX-like protein 1 RECQ1P46063ATP-dependent DNA helicase Q1 LY10LQ9H930Nuclear body protein SP140-like protein MBNL1Q9NR56Muscleblind-like protein 1 KCC2BQ13554Calcium/calmodulin-dependent protein kinase type II subunit beta LIPA3O75145Liprin-alpha-3 CD109Q6YHK3CD109 antigen ZN141Q15928Zinc finger protein 141 YTHD2Q9Y5A9YTH domain family protein 2 PLCDQ9NRZ51-acyl-sn-glycerol-3-phosphate acyltransferase delta KIFA3Q92845Kinesin-associated protein 3 TRI25Q14258E3 ubiquitin/ISG15 ligase TRIM25 ETUD1Q7Z2Z2Elongation factor Tu GTP-binding domain-containing protein 1 CDN1BP46527Cyclin-dependent kinase inhibitor 1B CO4A4P53420Collagen alpha-4(IV) chain TEX35Q5T0J7Testis-expressed sequence 35 protein MUC16Q8WXI7Mucin-16 NPIL2A6NJ64NPIP-like protein LOC729978 IRF2P14316Interferon regulatory factor 2 MK07Q13164Mitogen-activated protein kinase 7 APOAP08519Apolipoprotein(a) HIBCHQ6NVY13-hydroxyisobutyryl-CoA hydrolase, mitochondrial USH1CQ9Y6N9Harmonin GOG8OA6NCC3Golgin subfamily A member 8O NADEQ6IA69Glutamine-dependent NAD(+) synthetase MET17Q9H7H0Methyltransferase-like protein 17, mitochondrial PITH1Q9GZP4PITH domain-containing protein 1 IL1R1P14778Interleukin-1 receptor type 1 C1GLTQ9NS00Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 OR2L3Q8NG85Olfactory receptor 2L3 KV122P04430Ig kappa chain V-I region BAN GG8L2A6NP81Golgin subfamily A member 8-like protein 2 ZFYV1Q9HBF4Zinc finger FYVE domain-containing protein 1 CJ076Q5T2E6UPF0668 protein C10orf76 STAB 1Q9NY15Stabilin-1 EHBP1Q8NDI1EH domain-binding protein 1 ANR24Q8TF21Ankyrin repeat domain-containing protein 24 FAHD1Q6P587Acylpyruvase FAHD1, mitochondrial IWS1Q96ST2Protein IWS1 homolog THAP2Q9H0W7THAP domain-containing protein 2 FNIP1Q8TF40Folliculin-interacting protein 1 STK16O75716Serine/threonine-protein kinase 16 CXX1O15255CAAX box protein 1 GOG8RI6L899Golgin subfamily A member 8R SRRTQ9BXP5Serrate RNA effector molecule homolog ZN611Q8N823Zinc finger protein 611 MRE11P49959Double-strand break repair protein MRE11A LONMP36776Lon protease homolog, mitochondrial GOG8 NF8WBI6Golgin subfamily A member 8 N ALPK2Q86TB3Alpha-protein kinase 2 EI2BGQ9NR50Translation initiation factor eIF-2B subunit gamma NBPFLA6NDD8Neuroblastoma breakpoint family member 21 ETV7Q9Y603Transcription factor ETV7Table 4Proteins preferential to either HFpEF or control groupsProteinAccessionDescriptionp valueProteins preferentially found in HFpEF groupSAA2P0DJI9Serum amyloid A-2 protein0.0019SAA1P0DJI8Serum amyloid A-1 protein0.0019PHF3Q92576PHD finger protein 30.0090RGPD5Q99666RANBP2-like and GRIP domain-containing protein 5/60.0123RGPD8O14715RANBP2-like and GRIP domain-containing protein 80.0124YMEL1Q96TA2ATP-dependent zinc metalloprotease YME1L10.0256FHR2P36980Complement factor H-related protein 20.0269RGPD3A6NKT7RanBP2-like and GRIP domain-containing protein 30.0278CG010Q9HAC7CaiB/baiF CoA-transferase family protein C7orf100.0279RRBP1Q9P2E9Ribosome-binding protein 10.0279ZNF79Q15937Zinc finger protein 790.0279DCNL5Q9BTE7DCN1-like protein 50.0279RECQ1P46063ATP-dependent DNA helicase Q10.0283PERQ2Q6Y7W6PERQ amino acid-rich with GYF domain-containing protein 20.0285MBD5Q9P267Methyl-CpG-binding domain protein 50.0286GPCP1Q9NPB8Glycerophosphocholine phosphodiesterase GPCPD10.0286NOL10Q9BSC4Nucleolar protein 100.0351LBPP18428Lipopolysaccharide-binding protein0.0432AFF1P51825AF4/FMR2 family member 10.0442SOX30O94993Transcription factor SOX-300.0458DCP1AQ9NPI6mRNA-decapping enzyme 1A0.0465AN20BQ5CZ79Ankyrin repeat domain-containing protein 20B0.0468TCOFQ13428Treacle protein0.0479MEN1O00255Menin0.0486S10A8P05109S100A80.0808Proteins preferentially found in control groupMY15BQ96JP2Putative unconventional myosin-XVB0.0012ASXL3Q9C0F0Putative Polycomb group protein ASXL30.0045CC020Q9NX02NACHT, LRR and PYD domains-containing protein 20.0045TEKT1Q969V4Tektin-10.0070SEP10Q9P0V9Septin-10 OS = Homo sapiens0.0103LMNB2Q03252Lamin-B2 OS = Homo sapiens0.0103ZN469Q96JG9Zinc finger protein 4690.0146PARIQ9NWS1PCNA-interacting partner0.0148NOP2P46087Putative ribosomal RNA methyltransferase NOP20.0148FIGL2A6NMB9Putative fidgetin-like protein 20.0148MCTS1Q9ULC4Malignant T-cell-amplified sequence 10.0148TANC2Q9HCD6Protein TANC20.0148HEM0P225575-aminolevulinate synthase, erythroid-specific, mitochondrial0.0148PRP6O94906Pre-mRNA-processing factor 60.0148TACC2O95359Transforming acidic coiled-coil-containing protein 20.0200SMC3Q9UQE7Structural maintenance of chromosomes protein 30.0261GTF2IP78347General transcription factor II-I0.0262CI084Q5VXU9Uncharacterized protein0.0268CCSO14618Copper chaperone for superoxide dismutase0.0294COX6CP09669Cytochrome c oxidase subunit 6C0.0324INT11Q5TA45Integrator complex subunit 110.0352DCLK1O15075Serine/threonine-protein kinase DCLK10.0363SSH1Q8WYL5Protein phosphatase Slingshot homolog 10.0380PJA1Q8NG27E3 ubiquitin-protein ligase Praja-10.0390BRK1Q8WUW1Protein BRICK10.0422UBP44Q9H0E7Ubiquitin carboxyl-terminal hydrolase 440.0422PLCG2P168851-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-20.0428IGS22Q8N9C0Immunoglobulin superfamily member 220.0431RPGFLQ9UHV5Rap guanine nucleotide exchange factor-like 10.0431CN070Q86TU6Putative uncharacterized protein encoded by LINC005230.0431TRI35Q9UPQ4Tripartite motif-containing protein 350.0431TOPB1Q92547DNA topoisomerase 2-binding protein 10.0431R3HD4Q96D70R3H domain-containing protein 40.0431ABRQ12979Active breakpoint cluster region-related protein0.0431ZN441Q8N8Z8Zinc finger protein 4410.0431ZN451Q9Y4E5Zinc finger protein 4510.0431DCE2Q05329Glutamate decarboxylase 20.0431RAB31Q13636Ras-related protein Rab-310.0431PDE3AQ14432cGMP-inhibited 3′, 5′-cyclic phosphodiesterase A0.0431TRPM2O94759Transient receptor potential channel subfamily M member 20.0431C163BQ9NR16Scavenger receptor cysteine-rich type 1 protein M1600.0431CA094Q6P1W5Uncharacterized protein C1orf940.0431RSBN1Q5VWQ0Round spermatid basic protein 10.0431GRM8O00222Metabotropic glutamate receptor 80.0431KLHL7Q8IXQ5Kelch-like protein 70.0431SHAN3Q9BYB0SH3 and multiple ankyrin repeat domains protein 30.0431TTI1O43156TELO2-interacting protein 1 homolog0.0431FMO4P31512Dimethylaniline monooxygenase \[N-oxide-forming\] 40.0431RARBP10826Retinoic acid receptor beta0.0431UTYO14607Histone demethylase UTY0.0431SLKQ9H2G2STE20-like serine/threonine-protein kinase0.0431RB39BQ96DA2Ras-related protein Rab-39B0.0435RB43LA6NDJ8Putative Rab-43-like protein0.0435RAB4BP61018Ras-related protein Rab-4B0.0435RAB12Q6IQ22Ras-related protein Rab-120.0435RAB43Q86YS6Ras-related protein Rab-430.0435RAB30Q15771Ras-related protein Rab-300.0435GRM7Q14831Metabotropic glutamate receptor 70.0435ZNF67Q15940Putative zinc finger protein 726P10.0435FAKD5Q7L8L6FAST kinase domain-containing protein 50.0435ZNF98A6NK75Zinc finger protein 980.0435MFSD9Q8NBP5Major facilitator superfamily domain-containing protein 90.0435RECKO95980Reversion-inducing cysteine-rich protein with Kazal motifs0.0435AL1A3P47895Aldehyde dehydrogenase family 1 member A30.0435VP37CA5D8V6Vacuolar protein sorting-associated protein 37C0.0435ZN492Q9P255Zinc finger protein 4920.0435VPS29Q9UBQ0Vacuolar protein sorting-associated protein 290.0435HNRCLO60812Heterogeneous nuclear ribonucleoprotein C-like 10.0435DHRS7Q9Y394Dehydrogenase/reductase SDR family member 70.0452BRD8Q9H0E9Bromodomain-containing protein 80.0455IF2PO60841Eukaryotic translation initiation factor 5B0.0455GDPD3Q7L5L3Glycerophosphodiesterase domain-containing protein 30.0456SYSCP49591Serine--tRNA ligase, cytoplasmic0.0465NEK9Q8TD19Serine/threonine-protein kinase Nek90.0473p values are calculated based on the non-parametric Wilcoxon rank-sum tests

Discovery and validation cohort ELISA confirmation {#Sec16}
--------------------------------------------------

One particularly interesting finding was the identification of S100A8. The m/z ratio graph representing S100A8 is shown in Fig. [2](#Fig2){ref-type="fig"}. Even though the p value was 0.08, it was identified in six out of the nine HFpEF subjects. S100A8 has not been previously associated with HFpEF but has been linked to advanced heart failure \[[@CR23]\]. Additionally, S100A8 has been found to correlate with traditional cardiovascular risk factors and the manifestation of cardiovascular disease \[[@CR24], [@CR25]\]. For these reasons, we decided to look more closely at S100A8 to verify its association with HFpEF. S100A8 is found in platelets \[[@CR26], [@CR27]\] and the plasma \[[@CR25], [@CR28]\]; because we used the platelet lysates for the mass spect analysis, we used the plasma samples for quantitative ELISA analysis. Figure [3](#Fig3){ref-type="fig"} shows that plasma S100A8 levels are increased symptomatic HFpEF when compared to control (MCW cohort). We then validated these findings by studying a larger cohort of subjects recruited from the Northwestern University HFpEF Program. In this larger cohort, we saw a similar increase in plasma S100A8 levels in the HFpEF group (Fig. [3](#Fig3){ref-type="fig"}; Northwestern cohort).Fig. 2Representative MS/MS scan for S100A8 peptide sequence ALNSIIDVYHK. Raw m/z spectral images with peak assignments and *b* and *y* *ion* lists along with a representation of peptide sequencing by tandem mass spectrometryFig. 3Plasma levels of S100A8 in control vs. HFpEF groups. a S100A8 is found in increased levels in the plasma of subjects with HFpEF vs. control subjects as detected by ELISA. The MCW columns include the control (n = 7) and HFpEF (n = 9) from the discovery cohort and the NWU colums include the control (n = 18) and HFpEF (n = 25) samples from the validation cohort. *\*p* \< 0.006 vs MCW Control.^\#^ *p* \< 0. 002 vs NWU Control

Exogenously applied rS100A8 affects cardiomyocyte function in vitro {#Sec17}
-------------------------------------------------------------------

To ascertain whether S100A8 may play a causal role in the HFpEF disease process; we developed a bedside-to-bench translational system (Fig. [4](#Fig4){ref-type="fig"}) to screen for biological effects of identified proteins on cardiomyocyte function in vitro. We added recombinant S100A8 (800 ng/ml) to iPSC-derived cardiomyocytes in vitro and measured action potentials and intracellular Ca^2+^ concentrations separately. This specific concentration of rS100A8 was selected as it was the average plasma concentration observed in the HFpEF group (Fig. [3](#Fig3){ref-type="fig"}).Fig. 4Overview of primary and secondary screening methods to identify potential mediators of HFpEF. **a** Platelet proteomes were subject to mass spectral analysis and novel proteins were identified. **b** Human cardiomyocytes derived from induced pluripotent stem cells were used to determine whether proteins that were identified in **a** had direct effects on cardiomyocytes function in vitro. Purified recombinant protein S100A8 was tested in this assay

Action potentials (APs) were recorded in the current clamp mode using the patch clamp technique. The recordings were acquired from spontaneously beating cells. External application of rS100A8 slowed the spontaneous pacing within 25 s which suggests the interaction with a membrane receptor. In the example shown in Fig. [5](#Fig5){ref-type="fig"}a, the spontaneous generation of APs with atrial-like properties was slowed in the presence of rS100A8. The peak-to-peak AP interval increased from 1.5 to 2.4 s. This effect was reversible upon washout of rS100A8 (results not shown). In a different beating cell cluster, the recorded atrial-like APs showed arrhythmogenic tendencies characterized by infrequent incidents of failed triggering of APs, as shown in Fig. [5](#Fig5){ref-type="fig"}b. The rS100A8 exacerbated this trend by increasing the frequency of these failed events. Thus, the electrophysiological profile of these iPSC-derived cardiomyocytes is profoundly impacted by rS100A8.Fig. 5S100A8-mediated effects on human iPSC-derived cardiomyocytes. **a** Shows example action potentials recorded from rS100A8 treated iPSC derived human cardiomyocytes. The addition of rS100A8 to the buffer extended the period between action potentials. This period is phase 4; the diastolic membrane potential between action potentials. **b** rS100A8 exacerbates the arrhythmic tendencies of human cardiomyocytes. **c** Spontaneous Ca^2+^ transients recorded from human cardiomyocytes treated with rS100A8 as indicated by the blue line. rS100A8 significantly delayed the recovery of depolarization. Wash out of rS100A8 reversed these effects

Intracellular Ca^2+^ concentrations (\[Ca^2+^\]~i~) were measured using the ratiometric Ca^2+^ microfluorometry technique with Fura-2-AM fluorescent dye. The \[Ca^2+^\]~i~ were monitored in spontaneously beating cells. The sample trace (Fig. [5](#Fig5){ref-type="fig"}c) shows a spontaneous Ca^2+^ transient recording that was interrupted by activity-induced depolarization (50 mM K^+^; duration of application as noted) at certain time points (indicated by the red arrows) using a microperfusion system. Of particular note is the recovery of the spontaneous Ca^2+^ transient following each depolarizing pulse. In the absence of rS100A8, the recovery was relatively fast. In contrast, the recovery was considerably slower in the presence of rS100A8. Following a third depolarizing pulse, recovery was not evident until the washout of rS100A8; this observation also suggests that rS100A8 effects are mediated through a membrane receptor. In summary, rS100A8 adversely affected the calcium handling of iPSC-derived cardiomyocytes.

Conclusions {#Sec18}
===========

The key finding of this study was that it was possible to derive platelet protein data sets specific for HFpEF patients. These proof-of-concept findings suggest that the platelet proteome might provide a useful tool for screening for HFpEF-associated biomarkers. Although several platelet proteins were identified in HFpEF subjects; their exact connection to HFpEF has yet to be determined. Though our data is limited by the small size, our discovery cohort has similar characteristics of larger HFpEF cohorts reported in the literature \[[@CR29]--[@CR31]\]. By combining proteomics with bioactivity assays, we have demonstrated that the platelet proteome is an untapped resource for determining disease mediators in HFpEF.

The platelet proteome in healthy individuals is remarkably stable with only minor differences in protein expression patterns \[[@CR32]\]. Veitinger et al. suggests the difference in platelet proteins between individuals is a results of the uptake of plasma proteins by the platelet \[[@CR33]\]. Inflammation is closely linked with HFpEF \[[@CR34]\] and considering that platelets are involved in the inflammatory process, it is not surprising that our proteomics screen led to the identification of several proteins also involved in inflammation. These include serum amyloid A (SAA), Lipopolysaccharide binding protein, apolipoprotein A1 and S100A8. Two proteins, serum amyloid-A (SAA) protein 1 and apolipoprotein A1 were increased in the sera of non-human primates after drug-induced cardiac injury \[[@CR35]\]. In addition, increased levels of SAA in serum have been associated with coronary heart disease \[[@CR36]\], as well as systolic heart failure \[[@CR37]\] and has been shown to be a predictor of cardiovascular outcomes in women \[[@CR38]\].

S100A8 is a member of the S100 calcium-binding family of proteins, which exhibit increased levels in a number of inflammatory states. S100A8 is commonly mentioned with its binding partner, S100A9. Even though S100A8 is found in the plasma \[[@CR23]\], it is known that platelets and megakaryocytes might serve as an additional source of S100A8 and might contribute to the plasma pool of S100A8/A9 in inflammatory diseases and cardiovascular events \[[@CR26], [@CR27], [@CR39]\].

S100A8 and S100A9 are not normally expressed in cardiomyocytes \[[@CR40]\] although its cardiac expression can be induced by endotoxins or angiotensin II \[[@CR40], [@CR41]\]. Release of S100A8/A9 from cells allows it to act in a paracrine or autocrine fashion. These extracellular functions are mediated by the toll-like receptor 4 (TLR4) \[[@CR42], [@CR43]\] or the receptor for advanced glycation end products (RAGE) \[[@CR40], [@CR44], [@CR45]\]. More recently, CD36 has been identified as a receptor \[[@CR26]\]. In the mouse, S100A8/A9 signals through RAGE to promote inflammation and fibrosis after angiotensin II or hypoxic-induced cardiac injury \[[@CR41], [@CR45]\].

Increased platelet S100A8 mRNA and plasma protein levels were present in patients with acute myocardial infarction \[[@CR39]\]. Plasma levels of S100A8/A9 predicted risk of future myocardial infarction, stroke or death in post-menopausal healthy women \[[@CR25]\]. Elevated S100A8 levels have also been found in other inflammatory disorders which are associated with abnormalities of vascular and cardiac function, particularly diastolic dysfunction, such as diabetes \[[@CR46]--[@CR48]\], end-stage renal disease \[[@CR49], [@CR50]\], and inflammatory bowel disease \[[@CR51], [@CR52]\]. This is the first association of S100A8 with HFpEF, yet its role in the disease process still needs be elucidated. S100A8 has immediate effects on the electrophysiological and Ca^2+^ handling profiles of human induced cardiomyocytes suggesting that S100A8 is acting through a membrane receptor. S100A8 interaction with RAGE affects calcium flux in neonatal rat ventricular cardiomyocytes and HL-1 cardiomyocytes \[[@CR40], [@CR53]\]. The adverse effects on the electrophysiological and Ca^2+^ handling profiles resulting from S100A8 treatment of human induced cardiomyocytes; validates our bedside-to-bench translational screen as an approach to identify bioactive proteins that may contribute to the disease mechanisms in HFpEF.

We also considered the possibility that subjects progress to HFpEF through loss of cardioprotective proteins. Therefore, we searched amongst our control group and were able to identify four proteins that could potentially have protective qualities against the development of heart failure. Cyclic nucleotide phosphodiesterase 3A1 (PDE3A) regulates β-adrenergic signaling to effect physiological cardiac performance. Furthermore, PDE3A protects the heart against angiotensin II-induced cardiac remodeling in mice \[[@CR54]\]. Copper Chaperone for Superoxide Dismutase (CCS) plays a role in copper delivery to tissues; disturbances in copper homeostasis mediates cardiomyopathy \[[@CR55]\]. Zinc finger protein 451 a negative regulator of TGF-beta signaling \[[@CR56]\]. The transient receptor potential cation channel subfamily M member 2 (TRPM2) protein limits oxidative stress injury and dampens the inflammatory response \[[@CR57]\].

The present study must be interpreted within the context of its limitations. First of all, this was a discovery effort and not designed as a quantitative proteomic analysis. Therefore, we cannot determine if specific proteins are up- or down-regulated. In addition, it is unlikely that one protein is responsible for a complex disease as HFpEF, but our findings offer new perspectives regarding HFpEF and further confirmation of the platelet proteins identified in this study will need to be validated in a larger cohort. In addition, combining proteomics with functional bioactivity assessments may be a strategy to complement and strengthen the search for biomarkers by combining protein identified with biological activity in a relevant in vitro model system.

In conclusion, from the discovery set in HFpEF patients, we derived a panel of platelet proteins that may be specific for HFpEF. Furthermore, this set distinguished a set of platelet proteins which are consistent in HFpEF subjects whether they are decompensated and hospitalized or compensated after discharge. We further established a bedside-to-bench translational system that can be utilized as a secondary screen to ascertain whether the biomarkers may be an associated finding or causal to the disease process.
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10.1186/s12967-016-0774-3 Flow cytometry to assess platelet activation. Purified platelet samples were incubated with fluorescently labeled antibodies against CD62P and CD41 and subject to flow cytometry. Platelets positive for CD41 + but negative for CD62P are non-activated. CD62P positive platelets are activated.10.1186/s12967-016-0774-3 Microscopy for Platelet Purity. Isolated platelets were observed under the microscope. Visible red blood cells and leukocytes were counted and calculated as a percentage of platelets in each field. Microscopy confirmation verified that the purified platelet had a leukocyte contamination \< 0.02 % and a red blood cell contamination of \< 1 %.
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